Deepak Sambhara, MD, Eye Clinic of Wisconsin, discusses results from a post hoc analysis of the Phase 2/3 PHOTON trial investigating the impact of central retinal thickness on outcomes in patients with diabetic macular edema. Treatment with aflibercept 8 mg led to meaningful improvement in best-corrected visual acuity and central retinal thickness across baseline quartiles. According to Dr Sambhara, these results suggest that people with more swollen retinas at baseline have more VEGF that is circulating that should be suppressed. These results also highlight the benefit of a higher-dose VEGF agent that can contribute to initial VEGF suppression, especially in more difficult-to-treat patients with diabetic macular edema.